Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations

Development of resistance to kinase inhibitors remains a clinical challenge. Kinase domain mutations are a common mechanism of resistance in chronic myeloid leukemia (CML), yet the mechanism of resistance in the absence of mutations remains unclear. We tested proteins from the bone marrow microenvir...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Traer, Elie, Javidi-Sharifi, Nathalie, Agarwal, Anupriya, Dunlap, Jennifer, English, Isabel, Martinez, Jacqueline, Tyner, Jeffrey W., Wong, Melissa, Druker, Brian J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2014
Konular:
Myeloid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3945862/
https://ncbi.nlm.nih.gov/pubmed/24408322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-07-518381
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller